| Phase 11 trial |
|
Phase 1
|
NCT04050709 |
Jul 2019 → Mar 2021 |
metastatic malignant neoplasm |
ImmunityBio, Inc. |
Completed
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT06061809 |
Aug 2024 → Dec 2029 expected |
glioblastoma |
ImmunityBio, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06239220 |
Feb 2024 → Jul 2026 overdue |
head and neck squamous cell carcinoma |
Glenn J. Hanna |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04847466 |
Dec 2021 → Dec 2025 |
gastroesophageal cancer, head and neck squamous cell carcinoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04390399 |
Jul 2020 → Oct 2025 overdue |
malignant pancreatic neoplasm |
ImmunityBio, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03228667 |
Dec 2018 → Aug 2029 expected |
cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma, gastric cancer +8 |
ImmunityBio, Inc. |
Active not recruiting
|
No outcome recorded
|